 |
|
|
| Nov. 2000 |
|
Established M's Science Corporation, and licensed rights to SA4503 (Msc1) from Santen Pharmaceuticals Co., Ltd. |
 |
| Apr. 2001 |
|
Started joint research program with Nagoya University on cancer treatment using a herpes simplex virus. |
|
| Apr. 2001 |
|
Received the Research Business Award on New Technology from Small & Medium Enterprises and Regional Innovation, JAPAN. |
|
| Jul. 2001 |
|
Relocated headquarters to Kobe Port Island. |
|
| Sep. 2001 |
|
Acquired exclusive rights to A-5021 in the areas of cancer gene therapy and anti-virus eye drops from Ajinomoto Co., Inc. |
|
| Dec. 2001 |
|
Completed Series A financing of approximately 328 million Yen (Lead Investor: JAFCO Co., Ltd.). |
|
| Mar. 2002 |
|
Presented at Kansai Bio Conference in Kobe. |
|
| Oct. 2002 |
|
Started Phase I clinical study with SA4503 (Msc1) in The Netherlands. |
|
| Feb. 2003 |
|
Presented at the 6th Nomura Bio Conference. |
|
| Mar. 2003 |
|
Completed Series B financing of approximately 463 million Yen (Lead Investor: JAFCO Co., Ltd.). |
|
| Mar. 2003 |
|
Presented at BIO TECH HELSINKI 03. |
|
Jul. 2003 |
|
Certified for Creative Technology Research & Development Business by the Bureau of Economy, Trade and Industry. |
|
Oct. 2003 |
|
Completed follow-on to Series B of approximately 212 million Yen. |
|
Feb. 2004 |
|
Completed Phase I clinical study of SA4503 (Msc1) in the Netherlands. |
|
Jul. 2004 |
|
Licensed certain rights of SA4503 to USA-based AGY Therapeutics Inc. |
|
Dec. 2004 |
|
Completed Series C of approximately 2,079 million Yen (Lead Investor: JAFCO Co., Ltd.). |
|
May 2005 |
|
Presented at 11th Nomura Bio Conference. |
|
Feb. 2006 |
|
Started the production of cGMP HF10 (Msc2) for P-I/II clinical study. |
|
Mar. 2006 |
|
Acquired AGY Therapeutics' Neuroregeneration Program in its entirety, including all intellectual property and SA4503 analogues. M's has exclusive rights to the whole molecule of SA4503. |
|
Apr. 2006 |
|
Completed human PET study of SA4503 (Msc1) in the Netherlands. |
|
Apr. 2006 |
|
Assumed AGY's IND for stroke to continue P-IIa clinical development. |
|
Sep. 2006 |
|
Completed Phase 1b clinical study of SA4503 in The Netherlands. |
|
Mar 2007 |
|
US IND filing for HF10 for P-I/II clinical study in head and neck cancer |
|
May 2007 |
|
Completed Series D financing of approximately 800 million Yen |
|
Aug 2007 |
|
Phase 2a trial in Major Depression with SA4503 approved in Europe |
|
Sep 2007 |
|
United States composition and utility patent granted for HF10 |
|
 Remove to Top |
|
